<p>拟议的交易仍需进行尽职调查、签署最终协议、获得监管批准以及符合纳斯达克上市要求；在此阶段，ABL S.A. 对 ABL Diagnostics 的控制权没有变化。</p>
<p>法国 WOIPPY--（商业资讯）-- 监管新闻：</p>
<p>ABL Diagnostics（Euronext: ABLD - ISIN: FR001400AHX6）通知其股东和市场，其控股股东 Advanced Biological Laboratories S.A.（“ABL S.A.”）与 ProPhase Labs, Inc.（“ProPhase，” 纳斯达克：PRPH）已签署一份非约束性意向书（“LOI”），关于拟议的反向合并，届时 ABL 将成为合并公司的大股东。</p>
<p>该意向书是初步的，不构成完成交易的义务，除非是通常的保密和费用条款。该提案仍需进行尽职调查、谈判和签署最终协议、获得监管批准、遵守纳斯达克上市要求以及其他通常的成交条件。各方的目标是在 60-90 天内签署最终协议。</p>
<p>根据现有信息，拟议的交易不会影响 ABL S.A. 对 ABL Diagnostics 的控制权，也不会触发强制性收购门槛。尽管如此，ABL Diagnostics 将与其顾问审查所有方面，并在适当情况下通知 AMF 并寻求豁免。</p>
<p>在美国，如果发生控制权变更和/或发行 20% 或更多股份，交易可能需要 ProPhase 股东的批准。ProPhase 仍需负责遵守纳斯达克/SEC 规则。</p>
<p>如果未达成协议。如果未签署最终协议，各方将继续独立运营；意向书并不构成完成交易的义务。</p>
<p><strong>MAR 通知 — 内部信息</strong></p>
<p>本新闻稿包含根据欧盟法规（EU）第 596/2014 号第 17 条定义的内部信息。ABL Diagnostics 尽快披露此类信息。如决定延迟披露，将根据适用法规和指导方针处理并通知 AMF。本发布将在 ABL Diagnostics 网站的 “监管信息” 部分存档至少 5 年。</p>
<p><strong>前瞻性声明</strong></p>
<p>本发布可能包含基于假设的前瞻性声明，并受到可能导致实际结果显著不同的风险和不确定性的影响。ABL Diagnostics 不承担更新的义务，除非法律要求。</p>
<p><strong>关于 ABL Diagnostics（ABLD）</strong></p>
<p>ABL Diagnostics（ABLD）是一家国际公司，专注于创新的分子生物学检测和全球解决方案，服务于其客户：</p>
<ul>
<li>分子聚合酶链反应（PCR）检测 – UltraGene，以及</li>
<li>通过 DNA 测序进行基因分型 – DeepChek®。</li>
</ul>
<p>ABL Diagnostics 通过自己的销售团队和活跃于所有大洲的独家分销商网络在全球市场销售其全部产品。ABL Diagnostics 的客户包括学术临床病理实验室、私人参考实验室以及希望实施创新和稳健的微生物内容的研究人员。</p>
<p>自 2025 年下半年以来，ABL Diagnostics 通过内部战略协议营销其姐妹公司 CDL Pharma 的产品和服务。</p>
<p><strong>不断扩展的微生物学产品组合：</strong></p>
<ul>
<li>HIV – 药物耐药性检测，包括全基因组试剂盒。</li>
<li>SARS-CoV-2、结核病、乙型和丙型肝炎 – 先进的检测解决方案。</li>
<li>微生物组和分类 – 基于 16s/18s RNA 的分析。</li>
<li>其他病毒和细菌靶标 – 综合分子检测。</li>
</ul>
<p><strong>综合解决方案</strong></p>
<ul>
<li>实时综合 PCR 检测</li>
<li>Nadis® – 在法国 200 多家医院用于 HIV 和肝炎管理的患者医疗记录。</li>
<li>MediaChek® – 临床样本采集试剂盒。</li>
</ul>
<p>ABL Diagnostics 总部位于 Woippy，是一家在巴黎 Euronext 受监管市场 B 类上市的公众有限公司（Euronext: ABLD – ISIN: FR001400AHX6）。这些分子生物学产品产生经常性收入，并涵盖微生物学中最大的应用组合之一。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg5ODQ3OTVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg5ODQ3OTVyMQ"/></p>
<p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20251218984795/en/</p>
<p><strong>ABL Diagnostics SA</strong></p>
<p>股份公司，注册资本为 1,611,465.60 欧元</p>
<p>总部：72C route de Thionville - 57140 WOIPPY</p>
<p>552 064 933 R.C.S. METZ</p>
<p>电话：+33 (0) 7 83 64 68 50</p>
<p>电子邮件：<strong>info@abldiagnostics.com</strong></p>
<p><strong>https://www.abldiagnostics.com/</strong></p>
<p>来源：ABL Diagnostics</p>

PRPH

<p>ABL Diagnostics 宣布其控股股东 ABL S.A. 与 ProPhase Labs 之间达成了一份非约束性的意向书，拟进行反向合并。该交易需经过尽职调查、监管审批和纳斯达克的要求。ABL S.A. 将成为合并后公司的主要股东。该意向书为初步文件，未对最终达成交易产生任何义务，目标是在 60-90 天内达成最终协议。目前该交易不会影响 ABL S.A. 对 ABL Diagnostics 的控制权</p>

<p><em>The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’s control over ABL Diagnostics at this stage.</em></p>
<div class="lb-trans"><p>拟议的交易仍需进行尽职调查、签署最终协议、获得监管批准以及符合纳斯达克上市要求；在此阶段，ABL S.A. 对 ABL Diagnostics 的控制权没有变化。</p>
</div><p>WOIPPY, France--(BUSINESS WIRE)--Regulatory News:</p>
<div class="lb-trans"><p>法国 WOIPPY--（商业资讯）-- 监管新闻：</p>
</div><p>ABL Diagnostics (Euronext: ABLD - ISIN: FR001400AHX6) informs its shareholders and the market that Advanced Biological Laboratories S.A. (“ABL S.A.”), its controlling shareholder, and ProPhase Labs, Inc. (“ProPhase,” Nasdaq: PRPH) have signed a non‑binding letter of intent (the “LOI”) regarding a proposed reverse merger pursuant to which ABL would become the majority owner of the combined company.</p>
<div class="lb-trans"><p>ABL Diagnostics（Euronext: ABLD - ISIN: FR001400AHX6）通知其股东和市场，其控股股东 Advanced Biological Laboratories S.A.（“ABL S.A.”）与 ProPhase Labs, Inc.（“ProPhase，” 纳斯达克：PRPH）已签署一份非约束性意向书（“LOI”），关于拟议的反向合并，届时 ABL 将成为合并公司的大股东。</p>
</div><p>The LOI is preliminary and creates no obligation to consummate a transaction, other than customary confidentiality and expense provisions. The proposal remains subject to due diligence, negotiation and execution of definitive agreements, regulatory approvals, compliance with Nasdaq listing requirements, and other customary closing conditions. The parties are targeting an indicative 60–90‑day timeframe to execute definitive agreements.</p>
<div class="lb-trans"><p>该意向书是初步的，不构成完成交易的义务，除非是通常的保密和费用条款。该提案仍需进行尽职调查、谈判和签署最终协议、获得监管批准、遵守纳斯达克上市要求以及其他通常的成交条件。各方的目标是在 60-90 天内签署最终协议。</p>
</div><p>Based on the information available, the contemplated transaction does not affect ABL S.A.’s control over ABL Diagnostics and does not trigger the mandatory offer threshold. ABL Diagnostics will nevertheless review all aspects with its advisors and, where appropriate, will notify the AMF and seek a waiver.</p>
<div class="lb-trans"><p>根据现有信息，拟议的交易不会影响 ABL S.A. 对 ABL Diagnostics 的控制权，也不会触发强制性收购门槛。尽管如此，ABL Diagnostics 将与其顾问审查所有方面，并在适当情况下通知 AMF 并寻求豁免。</p>
</div><p>In the United States, the transaction may require approval by ProPhase shareholders in the event of a change of control and/or an issuance of 20% or more. ProPhase remains responsible for compliance with Nasdaq/SEC rules.</p>
<div class="lb-trans"><p>在美国，如果发生控制权变更和/或发行 20% 或更多股份，交易可能需要 ProPhase 股东的批准。ProPhase 仍需负责遵守纳斯达克/SEC 规则。</p>
</div><p>If no agreement is reached. If no definitive agreements are executed, each party will continue operating independently; the LOI does not create an obligation to consummate a transaction.</p>
<div class="lb-trans"><p>如果未达成协议。如果未签署最终协议，各方将继续独立运营；意向书并不构成完成交易的义务。</p>
</div><p><strong>MAR notices — Inside information</strong></p>
<div class="lb-trans"><p><strong>MAR 通知 — 内部信息</strong></p>
</div><p>This press release contains inside information within the meaning of Article 17 of Regulation (EU) No. 596/2014 (“MAR”). ABL Diagnostics discloses such information as soon as possible. Any delay in disclosure, if decided, would be handled and notified to the AMF in accordance with applicable regulation and guidance. This release will be archived for at least 5 years in the ‘Regulatory Information’ section of ABL Diagnostics’ website.</p>
<div class="lb-trans"><p>本新闻稿包含根据欧盟法规（EU）第 596/2014 号第 17 条定义的内部信息。ABL Diagnostics 尽快披露此类信息。如决定延迟披露，将根据适用法规和指导方针处理并通知 AMF。本发布将在 ABL Diagnostics 网站的 “监管信息” 部分存档至少 5 年。</p>
</div><p><strong>Forward‑looking statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This release may include forward‑looking statements based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially. ABL Diagnostics undertakes no obligation to update, except as required by law.</p>
<div class="lb-trans"><p>本发布可能包含基于假设的前瞻性声明，并受到可能导致实际结果显著不同的风险和不确定性的影响。ABL Diagnostics 不承担更新的义务，除非法律要求。</p>
</div><p><strong>About ABL Diagnostics (ABLD)</strong></p>
<div class="lb-trans"><p><strong>关于 ABL Diagnostics（ABLD）</strong></p>
</div><p>ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:</p>
<div class="lb-trans"><p>ABL Diagnostics（ABLD）是一家国际公司，专注于创新的分子生物学检测和全球解决方案，服务于其客户：</p>
</div><ul>
<li>Molecular polymerase chain reaction (PCR) detection – UltraGene, and</li>
<li>Genotyping by DNA sequencing – DeepChek®.</li>
</ul>
<div class="lb-trans"><ul>
<li>分子聚合酶链反应（PCR）检测 – UltraGene，以及</li>
<li>通过 DNA 测序进行基因分型 – DeepChek®。</li>
</ul>
</div><p>ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.</p>
<div class="lb-trans"><p>ABL Diagnostics 通过自己的销售团队和活跃于所有大洲的独家分销商网络在全球市场销售其全部产品。ABL Diagnostics 的客户包括学术临床病理实验室、私人参考实验室以及希望实施创新和稳健的微生物内容的研究人员。</p>
</div><p>ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.</p>
<div class="lb-trans"><p>自 2025 年下半年以来，ABL Diagnostics 通过内部战略协议营销其姐妹公司 CDL Pharma 的产品和服务。</p>
</div><p><strong>An expanding portfolio of microbiology products:</strong></p>
<div class="lb-trans"><p><strong>不断扩展的微生物学产品组合：</strong></p>
</div><ul>
<li>HIV – Drug resistance testing, including a whole genome kit.</li>
<li>SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.</li>
<li>Microbiome and taxonomy – 16s/18s RNA-based analyses.</li>
<li>Other viral and bacterial targets – Comprehensive molecular assays.</li>
</ul>
<div class="lb-trans"><ul>
<li>HIV – 药物耐药性检测，包括全基因组试剂盒。</li>
<li>SARS-CoV-2、结核病、乙型和丙型肝炎 – 先进的检测解决方案。</li>
<li>微生物组和分类 – 基于 16s/18s RNA 的分析。</li>
<li>其他病毒和细菌靶标 – 综合分子检测。</li>
</ul>
</div><p><strong>Integrated Solutions</strong></p>
<div class="lb-trans"><p><strong>综合解决方案</strong></p>
</div><ul>
<li>Real-time syndromic PCR tests</li>
<li>Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.</li>
<li>MediaChek® – Clinical Sample Collection Kits.</li>
</ul>
<div class="lb-trans"><ul>
<li>实时综合 PCR 检测</li>
<li>Nadis® – 在法国 200 多家医院用于 HIV 和肝炎管理的患者医疗记录。</li>
<li>MediaChek® – 临床样本采集试剂盒。</li>
</ul>
</div><p>ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.</p>
<div class="lb-trans"><p>ABL Diagnostics 总部位于 Woippy，是一家在巴黎 Euronext 受监管市场 B 类上市的公众有限公司（Euronext: ABLD – ISIN: FR001400AHX6）。这些分子生物学产品产生经常性收入，并涵盖微生物学中最大的应用组合之一。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg5ODQ3OTVyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251218984795r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251218984795/en/</p>
<div class="lb-trans"><p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20251218984795/en/</p>
</div><p><strong>ABL Diagnostics SA</strong></p>
<div class="lb-trans"><p><strong>ABL Diagnostics SA</strong></p>
</div><p>Société anonyme au capital de 1 611 465,60 euros</p>
<div class="lb-trans"><p>股份公司，注册资本为 1,611,465.60 欧元</p>
</div><p>Headquarters : 72C route de Thionville - 57140 WOIPPY</p>
<div class="lb-trans"><p>总部：72C route de Thionville - 57140 WOIPPY</p>
</div><p>552 064 933 R.C.S. METZ</p>
<div class="lb-trans"><p>552 064 933 R.C.S. METZ</p>
</div><p>Tel : +33 (0) 7 83 64 68 50</p>
<div class="lb-trans"><p>电话：+33 (0) 7 83 64 68 50</p>
</div><p>Email : <strong>info@abldiagnostics.com</strong></p>
<div class="lb-trans"><p>电子邮件：<strong>info@abldiagnostics.com</strong></p>
</div><p><strong>https://www.abldiagnostics.com/</strong></p>
<div class="lb-trans"><p><strong>https://www.abldiagnostics.com/</strong></p>
</div><p>Source: ABL Diagnostics</p>
<div class="lb-trans"><p>来源：ABL Diagnostics</p>
</div>

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger | PRPH Stock News

ABL Diagnostics 向市场通报 ABL S.A.与 Prophase Labs（纳斯达克代码：PRPH）之间拟议反向合并的非约束性意向书 | PRPH 股票新闻